RT Journal Article
SR Electronic
T1 Transcriptome- and proteome-wide Mendelian randomization to prioritize therapeutic targets for coronary heart disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.27.24309406
DO 10.1101/2024.06.27.24309406
A1 Gaziano, Liam
A1 Allara, Elias
A1 Giambartolomei, Claudia
A1 Stacey, David
A1 Zhao, Jing Hua
A1 Dashti, Hesam
A1 Jiang, Tao
A1 Ritchie, Scott C.
A1 Ferolito, Brian R
A1 Rasooly, Danielle
A1 Peloso, Gina M.
A1 Di Angelantonio, Emanuele
A1 Wheeler, Eleanor
A1 Pietzner, Maik
A1 Assimes, Themistocles L
A1 Wilson, Peter WF
A1 Cho, Kelly
A1 Aragam, Krishna G
A1 Burgess, Stephen
A1 Danesh, John
A1 Langenberg, Claudia
A1 Casas, Juan Pablo
A1 Michael Gaziano, J
A1 Pereira, Alexandre C
A1 Butterworth, Adam S
YR 2024
UL http://medrxiv.org/content/early/2024/06/28/2024.06.27.24309406.abstract
AB Despite widespread use of drugs targeting traditional cardiovascular risk factors such as lipids and blood pressure, a high burden of coronary heart disease (CHD) remains, hence novel therapeutics are needed for people who harbor residual risk. Using transcriptomic and proteomic data to instrument 15,527 genes or proteins, we conducted systematic cis-Mendelian randomization (MR) and conditional colocalization analyses with a genetic meta-analysis involving nearly 300,000 CHD cases. We identified 567 targets with putative causal relevance to CHD, of which 69 were not identified in previous genetic discovery or MR studies and were the sole causal signal in that genomic region. To aid translation of our findings, we annotated results with up-to-date information on drugs acting on these targets. Our results revealed opportunities for drug repurposing and development prioritization. For example, we provide evidence that cilostazol, a drug that targets PDE3A and is currently used for claudication, could be repurposed for prevention of CHD.Competing Interest StatementJ.P.C. moved to work with Novartis Institute for Biomedical Research during the completion of this project. E.W. is now an employee of AstraZeneca. A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. J. Danesh serves on scientific advisory boards for AstraZeneca, Novartis and the UK Biobank and has received multiple grants from academic, charitable and industry sources outside of the submitted work.Funding StatementScott C. Ritchie was funded by a British Heart Foundation (BHF) Programme Grant (RG/18/13/33946) and by the National Institute for Health and Care Research (NIHR) Cambridge BRC (BRC-1215-20014; NIHR203312) [*] * The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Emanuele Di Angelantonio holds an NIHR Senior Investigator Award. Stephen Burgess is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). John Danesh holds a British Heart Foundation Professorship and an NIHR Senior Investigator Award. Adam Butterworth and Claudia Langenberg were supported by BHF-DZHK grant funding 'Prot4CVD: Translational proteomics for cardiovascular diseases: from population prediction to clinical and therapeutic applications' (FKZ 81X2100281). The BHF Cardiovascular Epidemiology Unit was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), the NIHR BTRU in Donor Health and Behaviour (NIHR203337), the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014). This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division (Welsh Government), the Public Health Agency (Northern Ireland), the British Heart Foundation and Wellcome. Some analyses were performed using resources provided by the Cambridge Service for Data Driven Discovery (CSD3) operated by the University of Cambridge Research Computing Service (https://www.csd3.cam.ac.uk), provided by Dell EMC and Intel using tier 2 funding from the Engineering and Physical Sciences Research Council (capital grant EP/P020259/1), and DiRAC funding from the Science and Technology Facilities Council (https://www.dirac.ac.uk).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used several publicly available datasets: CHD summary statistics from Million Veteran Program (https://pubmed.ncbi.nlm.nih.gov/35915156/), CARDIoGRAMplusC4D Consortium (https://pubmed.ncbi.nlm.nih.gov/36474045/), and FinnGen (https://www.finngen.fi/en). PheWAS queries from MR Base (https://pubmed.ncbi.nlm.nih.gov/29846171/; https://gwas.mrcieu.ac.uk/). QTL information from the Genotype-Tissue Expression (GTEx) project (https://pubmed.ncbi.nlm.nih.gov/23715323/) and the Fenland Study (https://pubmed.ncbi.nlm.nih.gov/34648354/; https://pubmed.ncbi.nlm.nih.gov/34819519/). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or supplementary files.